Status:

RECRUITING

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This phase II trial studies the side effects and how well cladribine and rituximab work in treating patients with hairy cell leukemia. Drugs used in chemotherapy, such as cladribine, work in different...

Detailed Description

PRIMARY OBJECTIVES: I. To demonstrate the efficacy in achieving complete response of combination of cladribine administered intravenously over 2 hours for 5 days followed by rituximab weekly for 8 we...

Eligibility Criteria

Inclusion

  • Age 18 years and older
  • Diagnosis of hairy cell leukemia (HCL) established by bone marrow examination
  • Patients with relapsed disease are eligible if they have had no more than one prior therapy
  • Women of child-bearing potential must use birth control (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the study
  • Performance status =\< 3
  • Creatinine less than or equal to 2.0 unless related to the disease
  • Bilirubin less than or equal to 3.0
  • Transaminases less than or equal 3 x upper limit of normal unless related to the disease
  • No prior investigational agent in the 4 weeks prior to initiation of therapy

Exclusion

  • Unable or unwilling to sign the consent form
  • Known infection with human immunodeficiency virus (HIV), hepatitis B or C
  • Presence of active infection
  • Presence of central nervous system (CNS) metastases
  • New York Heart Association classification III or IV heart disease
  • Prior chemotherapy (last 4 weeks)

Key Trial Info

Start Date :

June 10 2004

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00412594

Start Date

June 10 2004

End Date

June 30 2027

Last Update

December 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030